Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04326192 · ClinicalTrials.gov registry record · NA
Brown Adipose Tissue Activation by Spinal Cord Stimulation
A NA study of Type 2 Diabetes and Obesity, Morbid, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04326192: Recruiting NA study of Type 2 Diabetes and Obesity, Morbid, sponsored by Oregon Health and Science University.
NCT04326192 is a NA study of Type 2 Diabetes and Obesity, Morbid that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 10 participants, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04326192, a NA study of Type 2 Diabetes and Obesity, Morbid, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to investigate and utilize spinal cord stimulation (SCS) as an effective approach to eliciting weight loss and potentially alleviating Type 2 diabetes mellitus (DM), as evidenced by increasing metabolism of adipose tissue.
Primary Outcome
Maximum standardized uptake value (SUVmax) of bilateral cervical and supraclavicular regions during SCS activation, in comparison to baseline imaging
Conditions Studied
Interventions
- DEVICE Research electrode
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-02-19 |
| Est. Completion | 2026-10 |
| Phase | NA |
What NCT04326192 shows while recruiting
NCT04326192 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Research electrode is the first listed.
NCT04326192 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT04326192 about?
NCT04326192 is a clinical study titled "Brown Adipose Tissue Activation by Spinal Cord Stimulation". The objective of this study is to investigate and utilize spinal cord stimulation (SCS) as an effective approach to eliciting weight loss and potentially alleviating Type 2 diabetes mellitus (DM), as evidenced by increasing metabolism of adipose tissue.
What is the current status of trial NCT04326192?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2021-02-19. Estimated completion is 2026-10.
What conditions does trial NCT04326192 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Obesity, Morbid, Pain, Back.
What interventions are being tested in trial NCT04326192?
The interventions under investigation include: Research electrode (DEVICE).
Who is sponsoring clinical trial NCT04326192?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04326192 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04326192's enrollment target sits among peer trials
10 321st of 327 higher than 4 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
RECRUITING · NA
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI